CagriSema REDEFINE-1: Key Results

Novo Nordisk announced topline results from the REDEFINE-1 Phase 3 trial evaluating CagriSema — a fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) — in adults with obesity. The combination achieved a 22.7% mean weight reduction from baseline at 68 weeks of treatment.

CagriSema combines two distinct metabolic pathways: cagrilintide mimics amylin, a hormone co-secreted with insulin that suppresses glucagon and slows gastric emptying, while semaglutide targets the GLP-1 receptor to reduce appetite and improve glycaemic control. The rationale for combination therapy is additive or synergistic weight loss through complementary mechanisms.

Context and Expectations

The 22.7% figure, while clinically significant, came in below the expectations of many analysts and below the bar Novo Nordisk had reportedly set for demonstrating clear superiority over semaglutide monotherapy. Semaglutide alone (Wegovy) has demonstrated approximately 15% weight loss in the STEP programme, meaning CagriSema's incremental benefit — roughly 7 percentage points — was less dramatic than anticipated.

This is particularly notable in the competitive landscape: Eli Lilly's tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist, achieved 20.2% weight loss in the SURMOUNT-5 head-to-head trial against semaglutide, and Lilly's triple-agonist retatrutide has reported even higher weight loss in Phase 3 TRIUMPH trials. CagriSema's results, while strong in absolute terms, may not provide a sufficient differentiation to establish market leadership.

Safety Profile

Novo Nordisk reported that CagriSema was generally well tolerated, with an adverse event profile consistent with the known effects of GLP-1 receptor agonists and amylin analogues. Gastrointestinal adverse events — nausea, vomiting, and diarrhoea — were the most commonly reported treatment-related adverse events, as expected for this drug class.

What This Means for Peptide Research

The REDEFINE-1 results underscore the potential of amylin-based combination therapy as a distinct therapeutic approach from dual or triple incretin receptor agonism. While the incretin pipeline (GLP-1, GIP, glucagon) has dominated obesity drug development, CagriSema represents the first late-stage test of combining amylin and GLP-1 pathways.

For researchers, the key questions emerging from REDEFINE-1 include:

  • Whether higher doses or longer treatment durations could yield greater separation from semaglutide monotherapy
  • Whether patient subgroups (e.g., those with higher baseline BMI or metabolic dysfunction) may derive greater benefit from the combination
  • How amylin-based combinations compare mechanistically to triple-agonist approaches targeting GLP-1, GIP, and glucagon

UK and European Implications

CagriSema is not currently licensed by the MHRA or the EMA. If Novo Nordisk proceeds with regulatory submissions based on the REDEFINE programme, the compound would enter the standard review pathway for new medicinal products in the UK and EU. As a prescription-only medicine, it would be subject to the same prescribing restrictions as Wegovy and Mounjaro.

For the research peptide community, cagrilintide — the amylin component of CagriSema — is already available from research chemical suppliers. The REDEFINE-1 data may increase research interest in cagrilintide both as a standalone agent and in combination protocols, though all such use remains strictly for research purposes and not for human consumption.

Next Steps

Novo Nordisk is expected to present full REDEFINE-1 data at an upcoming medical congress and publish results in a peer-reviewed journal. The company has indicated it is evaluating the broader REDEFINE programme, which includes REDEFINE-2 (studying CagriSema in type 2 diabetes), to determine the regulatory path forward.

The results also raise questions about whether Novo Nordisk will continue to invest in the CagriSema programme or pivot resources toward its earlier-stage pipeline, including oral GLP-1 candidates and next-generation incretin therapies.

This article is for research and educational purposes only. It does not constitute medical advice. CagriSema is an investigational compound not approved for human use outside of clinical trials.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.